Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Receives Consensus Rating of "Moderate Buy" from Analysts

Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Get Free Report) have been given an average recommendation of "Moderate Buy" by the thirteen research firms that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and ten have assigned a buy recommendation to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $351.67.

A number of brokerages recently weighed in on MDGL. HC Wainwright raised their target price on shares of Madrigal Pharmaceuticals from $390.00 to $400.00 and gave the stock a "buy" rating in a report on Tuesday, January 14th. Oppenheimer reduced their price objective on Madrigal Pharmaceuticals from $375.00 to $350.00 and set an "outperform" rating for the company in a research note on Wednesday, October 23rd. Cantor Fitzgerald reaffirmed a "neutral" rating on shares of Madrigal Pharmaceuticals in a research report on Wednesday, November 20th. JMP Securities reiterated a "market outperform" rating and issued a $427.00 price target on shares of Madrigal Pharmaceuticals in a research report on Friday, January 10th. Finally, UBS Group boosted their price objective on Madrigal Pharmaceuticals from $411.00 to $441.00 and gave the stock a "buy" rating in a report on Friday, November 1st.

Insider Activity

In other Madrigal Pharmaceuticals news, CEO William John Sibold sold 1,584 shares of the business's stock in a transaction on Friday, January 24th. The shares were sold at an average price of $335.24, for a total transaction of $531,020.16. Following the completion of the transaction, the chief executive officer now owns 54,303 shares of the company's stock, valued at $18,204,537.72. The trade was a 2.83 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Robert E. Waltermire sold 103 shares of the firm's stock in a transaction dated Friday, January 24th. The shares were sold at an average price of $335.24, for a total value of $34,529.72. Following the completion of the sale, the vice president now directly owns 4,955 shares in the company, valued at approximately $1,661,114.20. This represents a 2.04 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 12,090 shares of company stock valued at $3,883,621. Insiders own 22.80% of the company's stock.

Institutional Investors Weigh In On Madrigal Pharmaceuticals

Several hedge funds have recently modified their holdings of the business. Nisa Investment Advisors LLC raised its stake in Madrigal Pharmaceuticals by 47.6% during the 3rd quarter. Nisa Investment Advisors LLC now owns 211 shares of the biopharmaceutical company's stock valued at $45,000 after purchasing an additional 68 shares during the last quarter. Quest Partners LLC increased its holdings in shares of Madrigal Pharmaceuticals by 172.8% during the 3rd quarter. Quest Partners LLC now owns 581 shares of the biopharmaceutical company's stock worth $123,000 after purchasing an additional 368 shares during the period. Centaurus Financial Inc. acquired a new position in shares of Madrigal Pharmaceuticals during the second quarter valued at about $163,000. KBC Group NV lifted its stake in shares of Madrigal Pharmaceuticals by 73.5% in the fourth quarter. KBC Group NV now owns 609 shares of the biopharmaceutical company's stock valued at $188,000 after buying an additional 258 shares during the period. Finally, Truist Financial Corp acquired a new stake in Madrigal Pharmaceuticals during the second quarter worth about $216,000. 98.50% of the stock is owned by institutional investors.

Madrigal Pharmaceuticals Price Performance

NASDAQ MDGL traded down $2.47 on Friday, reaching $323.00. The company's stock had a trading volume of 506,181 shares, compared to its average volume of 460,176. The firm's 50 day moving average is $314.25 and its two-hundred day moving average is $276.20. The stock has a market cap of $7.04 billion, a PE ratio of -12.88 and a beta of -0.38. The company has a debt-to-equity ratio of 0.15, a quick ratio of 5.93 and a current ratio of 5.98. Madrigal Pharmaceuticals has a twelve month low of $168.25 and a twelve month high of $368.29.

Madrigal Pharmaceuticals Company Profile

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.